Speratum Biopharma
Speratum Biopharma is dedicated to transforming cancer treatment through innovative microRNA-based therapies and RNA technologies. Founded in 2014, the company leverages proprietary platforms such as Nano-In™, NoPass™, and miR-198 to develop targeted, effective therapeutics for solid tumors and other diseases. With a focus on precision medicine, Speratum aims to deliver safe, scalable, and life-changing treatments. The company is actively involved in research, clinical trials, and collaborations to advance oncology and infectious disease therapeutics, with a mission to deliver hope through innovation and scientific excellence.
Industries
Nr. of Employees
small (1-50)
Speratum Biopharma
Products
Lead miRNA-198 mimic therapeutic candidate
A microRNA-198 mimic formulated in a polymer nanoparticle delivery system designed to restore tumor-suppressor microRNA activity, reduce tumor burden, and sensitize tumors to chemotherapy in preclinical solid-tumor models.
Lead miRNA-198 mimic therapeutic candidate
A microRNA-198 mimic formulated in a polymer nanoparticle delivery system designed to restore tumor-suppressor microRNA activity, reduce tumor burden, and sensitize tumors to chemotherapy in preclinical solid-tumor models.
Services
Recruitment, onboarding, and operational support for physician investigators and clinical trial sites, including training and study resources to facilitate participation in investigational trials.
Recruitment, onboarding, and operational support for physician investigators and clinical trial sites, including training and study resources to facilitate participation in investigational trials.
Expertise Areas
- Precision oncology
- microRNA mimic therapeutics
- RNAi and miRNA sequence design and optimization
- Polymer nanoparticle-based nucleic-acid delivery
Key Technologies
- microRNA mimic therapeutics
- RNAi/miRNA sequence optimization algorithms
- Polymer nanoparticle delivery (PLGA-modified PEI formulations)
- Receptor-mediated targeting of nanoparticles
News & Updates
Various recent articles and research papers published in 2024 related to microRNA, nanotechnology, and cancer therapeutics.
A comprehensive review of mRNA therapeutics and gene delivery systems published in December 2024.
An article discussing the control and loss of control of microRNAs in human health and disease.
Research on PLGA nanotechnology and its clinical applications in 2024.
Development of a novel miR-198 based therapy with proprietary delivery platforms, pending patent US20220145290A1.
Various recent articles and research papers published in 2024 related to microRNA, nanotechnology, and cancer therapeutics.
A comprehensive review of mRNA therapeutics and gene delivery systems published in December 2024.
An article discussing the control and loss of control of microRNAs in human health and disease.
Research on PLGA nanotechnology and its clinical applications in 2024.
Development of a novel miR-198 based therapy with proprietary delivery platforms, pending patent US20220145290A1.